SAR441000
Total Payments
$40,344
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $40,344 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $40,344 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR441000 Administered Intratumorally as Monoth | SANOFI US SERVICES INC. | $40,344 | 0 |
Top Doctors Receiving Payments for SAR441000
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $40,344 | 1 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $40,344
Product Information
- Type Drug
- Total Payments $40,344
- Total Doctors 0
- Transactions 1
About SAR441000
SAR441000 is a drug associated with $40,344 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2019 to 2019. In 2019, $40,344 was paid across 1 transactions to 0 doctors.
The most common payment nature for SAR441000 is "Unspecified" ($40,344, 100.0% of total).
SAR441000 is associated with 1 research study, including "A Phase 1 First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR441000 Administered Intratumorally as Monoth" ($40,344).